LLY Logo

Eli Lilly and Company (LLY) 

NYSE
Market Cap
$755.04B
Sector
Healthcare
Industry
Drug Manufacturers—General
Rank in Sector
470 of 971
Rank in Industry
8 of 12

Largest Insider Buys in Sector

LLY Stock Price History Chart

LLY Stock Performance

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Insider Activity of Eli Lilly and Company

Over the last 12 months, insiders at Eli Lilly and Company have bought $0 and sold $2.35B worth of Eli Lilly and Company stock.

On average, over the past 5 years, insiders at Eli Lilly and Company have bought $478.61M and sold $5.52B worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 29,992,668 shares for transaction amount of $374.91M was made by Kearny Acquisition Corp (director) on 2022‑11‑30.

List of Insider Buy and Sell Transactions, Eli Lilly and Company

2024-11-08SaleSVP, Finance, & CAO
900
<0.0001%
$803.38$723,042-5.21%
2024-09-03Sale10 percent owner
24,084
0.0026%
$966.69$23.28M-6.08%
2024-08-27Sale10 percent owner
24,552
0.0026%
$968.46$23.78M-5.42%
2024-08-26SaleSVP, Finance, & CAO
750
<0.0001%
$950.00$712,500-4.99%
2024-08-22Sale10 percent owner
3,196
0.0003%
$966.33$3.09M-5.23%
2024-07-10Sale10 percent owner
210,000
0.023%
$939.82$197.36M0.00%
2024-07-08Sale10 percent owner
93,593
0.01%
$918.64$85.98M0.00%
2024-07-05Sale10 percent owner
52,369
0.0056%
$915.18$47.93M0.00%
2024-07-03Sale10 percent owner
8,848
0.0009%
$915.31$8.1M0.00%
2024-07-01Sale10 percent owner
58,749
0.0063%
$915.26$53.77M0.00%
2024-06-28Sale10 percent owner
1,441
0.0002%
$915.02$1.32M0.00%
2024-06-25Sale10 percent owner
188,100
0.0198%
$903.82$170.01M-0.69%
2024-06-24Sale10 percent owner
17,229
0.0018%
$902.38$15.55M+1.09%
2024-06-20Sale10 percent owner
9,671
0.0011%
$902.67$8.73M+1.02%
2024-06-17Sale10 percent owner
194,978
0.021%
$885.91$172.73M+0.74%
2024-06-14Sale10 percent owner
15,022
0.0016%
$882.47$13.26M+1.48%
2024-06-10Sale10 percent owner
75,510
0.0079%
$860.78$65M+2.90%
2024-06-07Sale10 percent owner
139,490
0.0147%
$852.29$118.89M+4.55%
2024-06-06Sale10 percent owner
179,617
0.0189%
$837.82$150.49M+5.96%
2024-06-05Sale10 percent owner
20,383
0.0022%
$836.32$17.05M+6.59%

Insider Historical Profitability

18.03%
LILLY ENDOWMENT INC10 percent owner
96891978
10.2065%
$795.350434
Norton JohnaEVP, Global Quality
25428
0.0027%
$795.3504
Zakrowski Donald ASVP, Finance, & CAO
5480
0.0006%
$795.35027
TAUREL SIDNEYChairman
635952
0.067%
$795.3501
LECHLEITER JOHN Cformer director
160068
0.0169%
$795.3512<0.0001%
Ricks David APresident & CEO
157405
0.0166%
$795.3516+34.48%
Simmons Jeffrey NSVP&Pres. Elanco Animal Health
135458
0.0143%
$795.3506
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSA
132962
0.014%
$795.35018
Harrington Michael JSenior VP and General Counsel
110300
0.0116%
$795.3502
Fry Stephen FSVP, HR & Diversity
100211
0.0106%
$795.3508
GOLDEN CHARLES EExec. Vice President and CFO
93284
0.0098%
$795.3504
Crowe Maria APresident, Mfg. Operations
92484
0.0097%
$795.3503
SANTINI GINOSr.VP, Corp. Strategy & BD
81045
0.0085%
$795.3502
Lundberg Jan MEVP,Science&Tech and Pres. LRL
77420
0.0082%
$795.3505
TALLARIGO LORENZOPresident, Internat'l Opers.
76105
0.008%
$795.3507
Skovronsky DanielSVP, CSO, and Pres. LRL
75818
0.008%
$795.3520+34.08%
TAI JACKSON P
62857
0.0066%
$795.35120+14.08%
White Anne E.EVP & Pres, Lilly Neuroscience
57926
0.0061%
$795.3512+34.48%
Walsh Fionnuala MSVP, Global Quality
55618
0.0059%
$795.3503
Carmine Bryce D.EVP and Pres, Lilly Bio-Meds
51266
0.0054%
$795.35016
PAUL STEVEN MEVP, Science and Technology
50300
0.0053%
$795.3508
Mahony SusanSVP & Pres., Lilly Oncology
40685
0.0043%
$795.35011
Rice Derica WEVP-Global Services and CFO
38292
0.004%
$795.35013
ARMITAGE ROBERT ASr. VP and General Counsel
37162
0.0039%
$795.3501
Jonsson PatrikEVP&Pres, LLY Imm, LLY USA&CCO
36941
0.0039%
$795.3503
Tapiero JacquesSVP&Pres., Emerging Markets
33302
0.0035%
$795.35010
Smiley Joshua LSVP and CFO
31524
0.0033%
$795.3531+19.97%
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
23580
0.0025%
$795.3505
HORN KAREN Ndirector
23054
0.0024%
$795.3501
Nobles AnneChief Eth/Cmpl Ofcr & SVP, ERM
20937
0.0022%
$795.3502
Zulueta Alfonso GSVP & President, Lilly Int'l
18646
0.002%
$795.35016
Shah Aarti S.SVP & CIO
19087
0.002%
$795.3502
HANISH ARNOLD CChief Accounting Officer
17747
0.0019%
$795.3506
Connelly Deirdre PPresident, U.S. Operations
17737
0.0019%
$795.3501
Runge Marschall Sdirector
15436
0.0016%
$795.3510+30.13%
Deane Frank MPresident, Mfg. Operations
12124
0.0013%
$795.3504
Yuffa IlyaSVP & President, LLY Int'l
11624
0.0012%
$795.3502
O'Neill MylesSVP & Pres., Mfg. Operations
8469
0.0009%
$795.3503
Weems AlonzoEVP, ERM & CECO
7760
0.0008%
$795.3504
HOOVER R DAVIDdirector
1500
0.0002%
$795.3510+13.86%
Canute Scott APresident, Mfg. Operations
753
0.0001%
$795.3501
Shaw ChristiSVP and Pres., Lilly Bio-Meds
500
0.0001%
$795.3502
Bald Eagle Acquisition Corp10 percent owner
100
0%
$795.3510+7.66%
Tyto Acquisition Corp10 percent owner
100
0%
$795.3510+13.98%
Kearny Acquisition Corpdirector
100
0%
$795.3510+18.64%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Lilly Endowment$76.94B10.4198.9M-0.87%-$676.83M100
The Vanguard Group$56.59B7.6572.75M+1.58%+$882.06M1.04
BlackRock$50.78B6.8765.27M+1.41%+$706.35M1.11
PNC Financial Services$40.02B5.4151.44M-0.53%-$211.04M27.99
State Street$26.65B3.6134.26M+1.4%+$366.61M1.09
Fidelity Investments$26.51B3.5934.08M+3.77%+$962.38M1.77
Capital World Investors$19.09B2.5824.54M-8.96%-$1.88B3.17
PRIMECAP Management Co$16.53B2.2421.25M-4.26%-$736.22M12.14
T. Rowe Price$16.04B2.1720.61M-5.56%-$944.07M1.97
JPMorgan Chase$14.94B2.0219.2M-0.37%-$55.02M1.33
Geode Capital Management$12.86B1.7416.58M+3.88%+$480.73M1.09
Morgan Stanley$10.17B1.3813.07M+3.23%+$318.07M0.75
State Farm$9.84B1.3312.65M-22.68%-$2.89B8.86
Wellington Management Company$8.57B1.1611.02M-6.48%-$594.13M1.45
Bank of America$8.22B1.1110.57M+6.94%+$533.84M0.79
Northern Trust$6.87B0.938.84M-3.25%-$230.97M1.12
Capital Research Global Investors$6.25B0.858.03M+5.99%+$353.15M1.42
JENNISON ASSOCIATES LLC$5.81B0.797.47M-1.73%-$102M3.89
Legal & General$5.53B0.757.11M-0.31%-$16.98M1.28
Capital International Investors$5.42B0.736.97M+5.06%+$261.05M1.1
BNY Mellon$5.27B0.716.77M-8.34%-$479.42M0.99
Nuveen$4.11B0.565.29M-1.47%-$61.24M1.18
AllianceBernstein$3.72B0.54.79M-5.43%-$213.73M1.31
Fisher Asset Management Llc$3.65B0.494.69M+3.32%+$117.29M1.71
Charles Schwab$3.64B0.494.67M+2.49%+$88.46M0.79
Ubs Asset Management Americas Inc$3.59B0.494.62M+2.7%+$94.54M1.27
Goldman Sachs$3.52B0.484.52M-3.43%-$124.76M0.65
Amundi$3.04B0.434.07M+8.49%+$237.59M1.27
Franklin Templeton Investments$3.02B0.413.88M+66.95%+$1.21B0.9
GQG Partners$2.99B0.413.85M+20.25%+$504.19M4.82
Janus Henderson$2.78B0.383.58M+7.32%+$189.6M1.4
Dimensional Fund Advisors$2.65B0.363.41M+0.4%+$10.57M0.68
Invesco$2.45B0.333.15M+2.68%+$63.91M0.51
Deutsche Bank$2.44B0.333.14M+11.3%+$247.95M1.1
Massachusetts Financial Services Co Ma$2.42B0.333.11M-3.12%-$78.01M0.72
Dz Bank Ag Deutsche Zentral Genossenschafts Bank Frankfurt Am Main$2.4B0.333.09M+11.37%+$245.4M2.59
Ameriprise Financial$2.34B0.323.01M-4.63%-$113.54M0.65
Wells Fargo$2.27B0.312.92M-4.17%-$98.9M0.6
UBS$2.09B0.282.69M+5.71%+$113M0.62
Swiss National Bank$1.88B0.252.42M-4.23%-$83.09M1.23
Royal Bank of Canada$1.84B0.252.37M+0.65%+$11.81M0.44
Edgewood Management$1.81B0.252.32M+3.12%+$54.76M4.86
HSBC$1.7B0.232.19M+25%+$339.71M1.21
U.S. Bancorp$1.65B0.222.13M-1.58%-$26.64M2.3
Schroder Investment Management Group$1.65B0.222.12M-3.06%-$51.95M1.95
Barclays$1.64B0.222.11M-18.69%-$376.84M0.74
Sumitomo Mitsui Trust Holdings$1.62B0.222.08M-0.88%-$14.32M1.09
CalPERS$1.61B0.222.07M-3.97%-$66.78M1.13
American Century Investments$1.53B0.211.97M-0.36%-$5.51M0.94
Bank of Montreal$1.41B0.191.81M-5.39%-$80.54M0.44
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.